Prevent immunogenicity surprises in the clinic.
The ISPRI Evaluate™ report is a comprehensive evaluation of the immunogenic potential of a biologic therapeutic, leveraging EpiVax’s proprietary ISPRI™ in silico toolkit and key insights from immunogenicity experts. Beginning with a detailed review of your product’s primary amino acid sequence, this analysis delves into the candidate’s overall and regional immunogenic potential through the context of T cell epitope content and regulatory T cell epitope characterization. Regional ‘hotspots’ are identified, and overall risk is compared to similar products with known immunogenicity for benchmarking. The final report will serve multiple purposes throughout the development process, combining objective measures with expert opinions crucial for directing the next phases of R&D.
Modalities
What can ISPRI Evaluate™ do for you?
- Provide comprehensive immunogenicity data to include in:
Integrated Summary of Immunogenicity (IND-filing preparations)
Fundraising materials
Publications
Research grant applications
Internal product characterization/R&D strategy discussions
- Determine the overall and regional immunogenic potential of your lead candidate(s).
- Rank order lead candidates allowing for intelligent selection and promotion.
- Direct R&D strategies by reducing volume of downstream in vitro and in vivo immunogenicity studies, saving precious resources (typically 20-fold).
- Focus optimization on critical protein regions.
EpiVax will make recommendations on which potentially immunogenic regions of the sequence could be good targets for deimmunization and offer a list of suggested deimmunizing point mutations.
The team of experts will consider critical aspects of the proposed use and create a detailed report in which all findings are interpreted and put into clinical context, providing a clear roadmap of the next steps in your development process.
Need actionable immunogenicity data?
Learn more about ISPRI Evaluate™!
The EpiVax Roadmap
